Search results
Humira: the highs and lows of the world’s best-selling drug
Pharmaceutical Technology via Yahoo Finance· 5 days agoHumira, an arthritis medication with indications for colitis andpsoriasis is the world’s...
Polycystic Ovarian Syndrome: New Science Offers Old Remedy
Medscape· 5 days agoAn ancient Chinese remedy for malaria could offer new hope to the 10% of reproductive-age women...
Jude Bellingham fans discuss hyperpigmentation over footballer's appearance
Yahoo Life UK· 4 days agoRead more about skin conditions: How a healthy gut microbiome can give you better winter skin (Yahoo...
9 Face-Lifting Skincare Products Dermatologists Recommend For Fast, Visible Results This Summer
SheFinds via Yahoo News· 3 days agoIf you’ve become aware of the onset of fine lines and wrinkles or have been considering the...
JD Supra: AbbVie Files Notice of Data Breach Impacting the Health Information of Tens of Thousands...
JD Supra· 20 hours agoOn May 22, 2024, AbbVie, Inc. filed a notice of data breach with the Attorney General of Texas after discovering that confidential information that had been entrusted to the company was subject ...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 4 days agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...
16 Firming Serums Dermatologists Say To Use Daily To Tighten Skin, Hydrate, And Restore A Youthful...
SheFinds via Yahoo News· 22 hours agoSummer is well and truly here, which means we are all striving for the ultimate summer glow. We’ve...
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
Morningstar· 5 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 and a 52-week maintenance study, COMMAND2Data showed that clinical remission,
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the...
Morningstar· 3 days agoJohnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA ...
Previously Unknown Immune System Link Uncovered – Findings Could Lead to New Cancer Treatments
SciTechDaily· 6 days agoWeill Cornell scientists discovered a crucial link between two immune pathways involving IL-23 and...